Summary
Eighteen women with metastatic breast cancer previously untreated with chemotherapy were entered on a phase II trial of intravenous menogaril, a new anthracycline derivative. Treatment was given at 140 mg/m2 on days 1 and 8 of each 28 day cycle. The most common toxicities were leukopenia in all patients and burning and phlebitis at infusion sites in 72%. Serial assessment of cardiac function by resting and stress gated blood pool scans showed temporary decrements in ejection fraction in only 2 patients (11%). The response rate to the therapy was 19% [95% CI 0–38%] including 1 complete and 2 partial responses. The median time to relapse among responders was 6.5 months. Mean survival in all patients entered was 15.8 months from date of entry. Menogaril at this dose and schedule has modest activity as first line therapy for metastatic breast cancer but also has significant marrow and local toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Henderson IC: Chemotherapy for Advanced Disease. In: Bonadonna G. (ed) Breast Cancer; Diagnosis and Management. John Wiley and Sons, New York, 1984; 247–280
Weiss GR, Von Hoff DD, McGovren JP, Neil GL, Paque RE: Antitumor activity of 7-con-O-methylnogarol (7-OMEN) in the human tumor clonogenic assay (Abstr). Proc Am Assoc Cancer Res 24: 309, 1983
Neil GL, Kuentzel SL, McGovren JP: Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin. Cancer Treat Rep 63: 1971–1978, 1979
McGovren JP, Neil GL, Denlinger RH, Hall TL, Crampton SL, Swenberg JA: Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new anthracycline antitumor agent. Cancer Res 39: 4849–4855, 1979
Brown TD, Donehower RC, Grochow LB, Rice AP, Ettinger DS: A Phase I Study of Menogaril in Patients with Advanced Cancer. J Clin Oncol 5: 92–99, 1987
Oken MM, Creech RH, Tormey DC, Horton J, Davis MD, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Co-operative Oncology Group. Am J Clin Oncol 5: 649–655, 1982
Gottlieb J, Rivkin S, Spiegel SC, Hoogstraten B, O'Bryan R, Delaney FC, Singhakowinta A: Superiority of adriamycin over oral nitrosurea in patients with advanced breast cancer: Cancer 33: 519–526, 1974
Tormey DC: Adriamycin (NSC-123127) in breast cancer: An overview of studies. Cancer Chemother Rep 6: 319–327, 1975
Sessa C, Gunderson S, ten Bokkel-Huinink W, Renard J, Cavalli F: Phase II Study of Intravenous Menogaril in Patients with Advanced Breast Cancer. J Natl Cancer Inst 80: 1066–1069, 1988
Long HJ, Schaid DJ, Schutt AJ, Ingle JN, Loprinzc C, Edmondson JH: Phase II evaluation of Menogaril in women with metastatic breast cancer after failure of first line chemotherapy (Abstr) Proc Am Assoc Cancer Res 28: 198, 1987
Dodion P, Sessa C, Joss R, Crespeigne N, Williams Y, Kitt M, Abrams J, Finet C, Brewer JE, Adams WJ, Earhart RH, Rozencweig M, Kenis Y, Cavalli F: Phase I study of Intravenous Menogaril Administered Intermittently. J Clin Oncol 4: 767–774, 1986
Costanza ME, Korzun AH, Norton L, Rice MA, Wood WC: A fair trial of trimetrexate (TMTX) in advanced breast cancer (Abstr) Breast Cancer Res and Treat 12: 125, 1988
Joss RA, Monfardini S, Hansen M, Dombernowsky P, Renard J, Pinedo HM: Negative Phase II Trial of Menogaril in Squamous, Adeno- and Large Cell Carcinoma of the Lung. Eur J Cancer Clin Oncol 24: 263–265, 1988
Gunderson S, Monfardini S, Renard J, Van Glabbeke M, Pinedo H: Phase II Trial of Menogaril in Advanced Malignant Melanoma. An EORTC Trial. Eur J Cancer Clin Oncol 23: 1707–1708, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kennedy, M.J., Donehower, R.C., Grochow, L.B. et al. Phase II Studies. Invest New Drugs 8, 289–294 (1990). https://doi.org/10.1007/BF00171839
Issue Date:
DOI: https://doi.org/10.1007/BF00171839